RecruitingPhase 3

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

France880 participantsStarted 2025-06-02

Plain-language summary

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Antiretroviral (ARV) regimen for \>8 weeks prior to screening visit, with CD4 T-cell count \>200 cells/mm3 and plasma HIV-1 RNA \<LLOQ
✓. Suitable ARV treatment and not taking any contraindicated medications

Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24

Timeframe: Day 1 through Week 24

NCT IDNCT07037277

SponsorAtea Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

Clinical Trials Administrator